[Advance of postoperative adjuvant therapy in non-small cell lung cancer]

Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):501-5. doi: 10.3779/j.issn.1009-3419.2014.06.12.
[Article in Chinese]

Abstract
in English, Chinese

Lung cancer including non-small cell lung cancer (NSCLC) and SCLC is the most commonly diagnosed cancer and leading cause of cancer-related death worldwide. This review focuses on progress of the effect, indications, regimens and the related biological markers of postoperative adjuvant chemotherapy in NSCLC.

肺癌可分为非小细胞肺癌（non-small cell lung cancer, NSCLC）和小细胞肺癌，其发病率和死亡率均高居恶性肿瘤首位。本文主要就NSCLC术后辅助化疗的地位确立、辅助化疗的合适人群和化疗方案选择以及相关生物标志物研究进展作一综述。

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / surgery
  • Chemotherapy, Adjuvant*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / surgery
  • Postoperative Period